Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Nils E. van ‘t Veer"'
Autor:
Tessa Mulder, Marjolein F. Q. Kluytmans-van den Bergh, Anne Marie G. A. de Smet, Nils E. van ‘t Veer, Daphne Roos, Stavros Nikolakopoulos, Marc J. M. Bonten, Jan A. J. W. Kluytmans, PreCaution Study Group
Publikováno v:
Trials, Vol 19, Iss 1, Pp 1-9 (2018)
Abstract Background Colorectal surgery is frequently complicated by surgical site infections (SSIs). The most important consequences of SSIs are prolonged hospitalization, an increased risk of surgical reintervention and an increase in mortality. Per
Externí odkaz:
https://doaj.org/article/3ad337281f7a4d4ca9af7d6b17834355
Autor:
Rob ter Heine, Koen p van Rhee, Dirk Jan A.R. Moes, Annemieke Vermeulen Windsant, Peter Pickkers, Quirijn de Mast, Judith van Paassen, Roger J. M. Brüggemann, Jannette Rahamat-Langedoen, Birgit C. P. Koch, Roland R.J. van Kimmenade, Jeroen Schouten, Florens Polderman, Rutger van Raalte, Frank L. van de Veerdonk, Tim Frenzel, Paul D van der Linden, Monique H. Reijers, Nils E van 't Veer, David M. Burger, Mara van Rossum, Thijs C.D. Rettig
Structured abstractObjectiveChloroquine has been frequently administered for treatment of coronavirus disease 2019 but there are serious concerns about its efficacy and cardiac safety. Our objective was to investigate the pharmacokinetics and safety
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d20443eaa23feb350a9098d4dae1f993
Autor:
Joost B. Koedijk, Daan J Touw, C.G.H. Valk-Swinkels, Nils E. van 't Veer, Paul G.H. Mulder, Nardo J. M. van der Meer, Peter H. J. van der Voort, Tom A. Rijpstra
Publikováno v:
Antimicrobial Agents and Chemotherapy, 60(6), 3587-3590. AMER SOC MICROBIOLOGY
The objective of this study was to describe the pharmacokinetics of cefotaxime (CTX) in critically ill patients with acute kidney injury (AKI) when treated with continuous renal replacement therapy (CRRT) in the intensive care unit (ICU). This single
Autor:
Nico van Walree, Jeannine Huisbrink, Anton J.M. van Boxem, Sabine Visser, Bruno H. Stricker, Nils E. van ‘t Veer, Jermo J. van Toor, Joachim G.J.V. Aerts
Publikováno v:
European Respiratory Journal, 52(4):1800884. European Respiratory Society
Optimal survival benefit from different lines of anticancer treatment in advanced nonsmall cell lung cancer (NSCLC) requires conservation of renal function. We evaluated the development of renal impairment during pemetrexed maintenance.In a prospecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfcf7a56ff2b3b7d596138f93ed7ddb9
https://pure.eur.nl/en/publications/84295b6a-385a-4a25-b9c7-62bc1d293e2d
https://pure.eur.nl/en/publications/84295b6a-385a-4a25-b9c7-62bc1d293e2d
Autor:
Dimitri N.M. Papatsonis, Maureen A. ter Laak, Paul R.M. van Hattum, Frederik K. Lotgering, Martina Porath, Mariëlle G. van Pampus, Marc E. A. Spaanderman, Carolien Roos, Anneke Kwee, Nils E. van 't Veer, Joris A. M. van der Post, Daan J Touw, Ben W.J. Mol
Publikováno v:
International Journal of Clinical Pharmacology and Therapeutics, 53, 84-91
International Journal of Clinical Pharmacology and Therapeutics, 53, 1, pp. 84-91
International journal of clinical pharmacology and therapeutics, 53(1), 84-91. Dustri-Verlag Dr. Karl Feistle
International Journal of Clinical Pharmacology and Therapeutics, 53, 1, pp. 84-91
International journal of clinical pharmacology and therapeutics, 53(1), 84-91. Dustri-Verlag Dr. Karl Feistle
Item does not contain fulltext OBJECTIVE: The pharmacokinetics of nifedipine as a tocolytic agent has not been studied in great detail in pregnant women and has instead focused on immediate release tablets and gastrointestinal therapeutic system (GIT
Autor:
Eline A E van der Hagen, Nils E van 't Veer, Kristel J. M. Boonen, Antonius A.M. Ermens, Kees C.J. Smeekens
Publikováno v:
Clinical Chemistry and Laboratory Medicine (CCLM). 55
Autor:
Sevim Uzun, Nils E. van ‘t Veer, Jan Kluytmans, Henk C. Hoogsteden, Anton A.M. Ermens, Menno M. van der Eerden, Remco S. Djamin, Joachim G.J.V. Aerts
Publikováno v:
Clinical Pulmonary Medicine. 21:61-67
Chronic obstructive pulmonary disease (COPD) is one of the major health problems in the world. Long-term treatment with macrolide antibiotics is a recent development that has been reported to have beneficial effects on exacerbation frequency. These e
Autor:
Henk C. Hoogsteden, Remco S. Djamin, Aline J. Pelle, Paul G.H. Mulder, Sevim Uzun, Menno M. van der Eerden, Jan Kluytmans, Joachim G.J.V. Aerts, Nils E. van ‘t Veer, Anton A.M. Ermens
Publikováno v:
The Lancet Respiratory Medicine, 2(5), 361-368. Elsevier Ltd.
Lancet respiratory medicine, 2(5), 361-368. Elsevier Limited
Uzun, S, Djamin, R S, Kluijtmans, J A J W, Mulder, P G, Van't Veer, N E, Ermens, A A, Pelle, A J, Hoogsteden, H C, Aerts, JG & van der Eerden, M M 2014, ' Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial ', Lancet respiratory medicine, vol. 2, no. 5, pp. 361-368 . https://doi.org/10.1016/S2213-2600(14)70019-0
Lancet respiratory medicine, 2(5), 361-368. Elsevier Limited
Uzun, S, Djamin, R S, Kluijtmans, J A J W, Mulder, P G, Van't Veer, N E, Ermens, A A, Pelle, A J, Hoogsteden, H C, Aerts, JG & van der Eerden, M M 2014, ' Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial ', Lancet respiratory medicine, vol. 2, no. 5, pp. 361-368 . https://doi.org/10.1016/S2213-2600(14)70019-0
Summary Background Macrolide resistance is an increasing problem; there is therefore debate about when to implement maintenance treatment with macrolides in patients with chronic obstructive pulmonary disease (COPD). We aimed to investigate whether p
Autor:
Alphons H. Temmink, Paul R.M. van Hattum, Nils E. van 't Veer, Christa M. Cobbaert, Maureen A. ter Laak, Ankie Koeken
Publikováno v:
Pediatric Neurology. 43:159-162
Ten out of 100 children treated for attention deficit hyperactivity disorder with standard doses of atomoxetine were selected by a neurologist for cytochrome P450 2D6 and cytochrome P450 2C19 genotyping, based on late response (>9 weeks) and adverse
Autor:
Corinne G H, Valk-Swinkels, Fazil, Alidjan, Mirjam K, Rommers, René C, Bakker, Jesse J, Swen, Nils E, van 't Veer
Publikováno v:
Nederlands tijdschrift voor geneeskunde. 157(28)
Cyclosporin is an immunosuppressive agent with a wide range of therapeutic uses. In transplant patients, it is used for the prevention of rejection and graft-versus-host reactions. The metabolism and bioavailability of cyclosporin can be significantl